Manipal Hospitals Q1FY27: consolidated PAT down 4% YoY despite 38% revenue growth

Manipal Health Enterprises (Manipal Hospitals) reported consolidated revenue of ₹3,090.63 Cr for the quarter ended June 30, 2026, up 38.1% YoY (+7.2% QoQ), but consolidated net profit fell to ₹243.43 Cr, down 4.2% YoY (owners' share ₹231.65 Cr, down 7.5% YoY; EPS ₹1.96 vs ₹2.17 a year ago, -9.7%). Adjusting for the near-identical exceptional charge both years (₹15.47 Cr now vs ₹18.40 Cr YoY), adjusted PAT still fell roughly 4.6% YoY — this is not a one-off-driven decline, it is a genuine margin story. Standalone (parent-only) told the same story: revenue up 28.2% YoY to ₹1,048.30 Cr, PAT down 8.3% YoY to ₹115.53 Cr. The gap between strong topline growth and shrinking profit sits almost entirely on two lines: finance costs, which surged 123% YoY to ₹293.27 Cr (from ₹131.61 Cr), and depreciation, up 33% YoY to ₹187.25 Cr (from ₹140.63 Cr) — both consistent with debt-funded hospital acquisitions (notably the Sahyadri Hospitals controlling stake bought in October 2025) now sitting on the consolidated balance sheet for a full quarter versus none in the year-ago base. Consolidated net profit margin compressed to 7.7% from 11.1% a year ago, though it did improve sequentially from 6.4% in the March 2026 quarter, and operating profit margin (pre-exceptional PBT/total income) similarly moved to 10.4% from 15.9% YoY but up from 8.7% QoQ — sequential trends are healthier than the YoY trend, which is the one that matters for the verdict. We have no prior guidance or concall commentary on record for this company, and a web search turned up no analyst consensus estimates for this print either — this is the company's first quarterly result as a listed entity, having completed its ₹8,000 Cr fresh-issue IPO at ₹590/share on August 5, 2026, after this quarter had already closed, so the deleveraging benefit from IPO proceeds is not yet visible in these numbers. Two corporate actions from this reporting window are notable but not yet reflected in the P&L: the company signed a Business Transfer Agreement to acquire Kinder Women's Hospital, Bengaluru, for ₹130 Cr (subsequent to quarter-end, disclosed Aug 17-18, 2026), continuing the inorganic-growth pattern that is already driving the elevated finance-cost and depreciation base. Going into Q2 FY27, the key swing factor is whether IPO proceeds get applied to reduce the ₹293 Cr quarterly finance-cost run-rate, and whether margins continue the QoQ recovery seen this quarter (NPM 6.4% → 7.7%) toward the 11%+ levels of a year ago, once the Sahyadri and other recent acquisitions are past their initial integration and financing-cost drag.